Ignite Creation Date:
2024-05-06 @ 1:39 PM
Last Modification Date:
2024-10-26 @ 1:18 PM
Study NCT ID:
NCT04087473
Status:
RECRUITING
Last Update Posted:
2024-02-01
First Post:
2019-09-09
Brief Title:
Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC
Sponsor:
National Cancer Centre Singapore
Organization:
National Cancer Centre Singapore
Study Overview
Official Title:
Plasma Molecular Profiling in ALK Inhibitor Resistant Non-Small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators plan to understand a comprehensive molecular profiling via the plasma with the primary aim of using this form on analysis to guide subsequent treatment selection This study will provide a better understanding of ALK resistance in the treatment of Asian lung cancers and allow for improved clinical outcomes by matching the secondary mutations to an ALK inhibitor which would allow for the greatest coverage ultimately leading to lasting duration of response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None